Skip to content
FHI 360
  • Languages
  • Low bandwidth
  • High bandwidth
  • Search
  • Who we are
        • Who we are
          • About us
          • Leadership
          • Ethics and safeguarding
          • Impact and financial reports
          • Contact us
        • About us

          Impact and financial reports

  • What we do
        • What we do
          • Economic opportunity
          • Health


        • How we do it
          • Research in action
          • Humanitarian response
          • Digital innovation and AI
        • Explore our expertise
        • Economic opportunity

          Health

  • Where we work
        • Where we work
          • Asia Pacific
          • Central Africa
          • East Africa
          • West Africa
          • Southern Africa
          • Middle East and North Africa
          • Europe and Central Asia
          • Latin America and the Caribbean
          • United States
        • Around the world

          In the United States

  • Work with us
        • Work with us
          • Join our team
          • Local partners
          • Government and multilateral funders
          • Foundations and corporations
          • Academic and research partners
          • Small businesses and vendors
          • CEO position specification
        • Join our team

          Local partners

          Government and multilateral funders

          Foundations and corporations

          Academic and research partners

          Small businesses and vendors

  • News
        • News
          • Newsroom
        • Get the latest news
        • Newsroom

  • Stories
        • Stories & blog
          • Stories
          • Videos (YouTube)
          • Blog
        • Explore our storytelling
        • Our storytelling

          Blog

  • Resources
        • Resources
          • Resource library
        • Resource library

Home | Blog | COVID-19 vaccine hesitancy: The problem ahead
March 31, 2021

COVID-19 vaccine hesitancy: The problem ahead

–Thaddeus Pennas, Technical Advisor, Social and Behavior Change, FHI 360

Vaccines are here! The end of the pandemic is in sight! There is light at the end of the tunnel! Wait a minute. Is that really a light or the next more challenging phase of the pandemic speeding toward us? After more than a year of lockdown and restrictions, all of us have grown weary of the struggle and should be racing to get vaccinated. But we are not.

Polls in the United States suggest a vaccine acceptance rate of barely 51 percent. Polls from many low- and middle-income countries report only slightly better acceptance rates in the 55 percent to 60 percent range. More troubling, all the polls show an increase in vaccine hesitancy over time. With these already low and declining acceptance rates, how are we ever going to reach the magic 65-85 percent vaccination rate needed to achieve herd immunity?

Worse still is the challenge stated by Dr. Heidi Larson of the Vaccine Confidence Project. “The pandemic will soon enter a new phase when the pandemic wanes, cases drop, vaccine supply expands, restrictions ease and vaccine hesitancy rates spike. People and policymakers need to be ready with a roadmap to deal with falling vaccine acceptance and demand as the perceived risk or immediate threat of COVID-19 diminishes.” Currently, there are no comprehensive roadmaps for this phase of the pandemic and how we will combat vaccine hesitancy effectively.

What can be done to head off this looming problem that is just weeks away? There is no easy answer, but there are actions we can take:

  • Think about what is to come. Most policymakers and public health officials are consumed with vaccine production rates, rollout and logistical issues. They may soon realize that, although these are immediate problems, simply providing high-quality COVID-19 immunization services will likely not achieve the necessary vaccination rate. Every mass vaccination effort, from smallpox to polio to measles, learned the same lesson: Vaccine acceptance, social and community support for vaccination and combating vaccine hesitancy are an essential core strategy. Respected immunization champions, such as Dr. D.A. Henderson (smallpox), Drs. Stephen Cochi and Bruce Alyward (polio) and others, consistently list community mobilization and behavior change as game-changing strategies to fight vaccine hesitancy. The global community needs to quickly relearn these lessons and design strategies to address the growing vaccine hesitancy threat.
  • Prepare strategies and plans using social and behavior change tools, such as FHI 360’s Demand Creation and Advocacy for COVID-19 Vaccine Acceptance and Uptake: An Interim Quick Start Guide. It offers ways to target various audiences ranging from the easy-to-convince to the poorly reached, unconcerned and hesitant. This will allow policymakers and public health workers to tailor communication and community engagement to motivate people to seek immunizations.
  • Become conversant in strategies and approaches that address vaccine hesitancy, including the promotion of the benefits of vaccination. The benefits that will resonate include decreased mortality and morbidity to COVID-19, returning to school and traveling freely, and returning to normalcy. Provide information about the consequences of nonvaccination, such as the danger to personal and economic health if a community remains unvaccinated. Present real-life stories of people who have experienced COVID-19 and those who experienced the benefits of vaccination. Have a locally credible person speak in favor of vaccination, identify and compare pros and cons of vaccination, and offer incentives (when appropriate) to promote vaccination.

Sound public health interventions, like social distancing, mask wearing and quarantining, helped bring down the astronomically high number of daily new infections during the surge that took place in the winter of 2020-2021 in the northern hemisphere. We now need a comprehensive social and behavior change communication strategy to bring down the exceptionally high vaccine hesitancy rate. Or that proverbial light at the end of the tunnel may be farther away than we expect.

Share blog
Back to top
FHI 360

We are a nonprofit organization that mobilizes research, resources and relationships so that people everywhere can access the opportunities they need to lead full, healthy lives.

  • Partner with us
  • Business opportunities
  • Contract mechanisms
  • Small business
  • Our FHI 360 network
  • Events
  • Employee access
  • Contact us
  • Press
  • Privacy notice
  • Ethics and safeguarding

FHI 360 Headquarters
359 Blackwell Street, Suite 200
Durham, NC 27701 USA
1.919.544.7040

Washington, D.C., Office
2101 L St NW, Suite 700
Washington, DC 20037 USA
1.202.884.8000

Anti-trafficking statement

Connect

Sign up for our mailing list and receive the latest updates from FHI 360 straight to your inbox!

  • LinkedIn
  • Facebook
  • X
  • Youtube
  • Instagram

FHI 360 is the registered trade name of Family Health International.

©2026 FHI 360

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

FHI 360
Powered by  GDPR Cookie Compliance
Privacy overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Essential cookies

Essential cookies should be enabled at all times so that we can save your preferences for cookie settings. However, they can be enabled or disabled using the button below.

Non-essential cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.